You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
Harvard Business School
Baxter
Medtronic
Colorcon

Last Updated: September 25, 2020

DrugPatentWatch Database Preview

Patent: 9,353,171

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,353,171
Title:Use of pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP analogs for treating contrast-induced nephropathy
Abstract: Featured are methods and compositions for treating, managing, preventing, or reducing injury to the kidney of a mammal (e.g., a human) caused by one or more iodinated radiocontrast media. The methods include administering an effective amount of one or more pituitary adenylate cyclase-activating polypeptide (PACAP)-like compounds, which includes native human PACAP38, native human PACAP27, native human vasoactive intestinal peptide (VIP), their agonists, analogs, fragments, and derivatives, with activities toward one or more of the PACAP/VIP receptors, including all of their various isoforms. Also provided are pharmaceutical compositions of one or more PACAP-like compounds, either alone or in combination with one or more other prophylactic/therapeutic agents useful for treating, managing, or preventing injury to the kidney of a mammal (e.g., a human) undergoing treatment with one or more iodinated radiocontrast media. Also featured is an in vivo mouse model for testing the efficacy of cytoprotective agents against contrast-induced nephropathy.
Inventor(s): Batuman; Vecihi (New Orleans, LA), Maderdrut; Jerome L. (New Orleans, LA), Li; Min (New Orleans, LA), Coy; David H. (New Orleans, LA)
Assignee: The Administrators of the Tulane Educational Fund (New Orleans, LA)
Application Number:14/357,393
Patent Claims:see list of patent claims

Details for Patent 9,353,171

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Immunex ENBREL etanercept VIAL; SUBCUTANEOUS 103795 001 1998-11-02   Start Trial The Administrators of the Tulane Educational Fund (New Orleans, LA) 2031-11-17 RX Orphan search
Immunex ENBREL etanercept SYRINGE 103795 002 1998-11-02   Start Trial The Administrators of the Tulane Educational Fund (New Orleans, LA) 2031-11-17 RX Orphan search
Biovitrum Ab KEPIVANCE palifermin INJECTABLE; INJECTION 125103 001 2004-12-15   Start Trial The Administrators of the Tulane Educational Fund (New Orleans, LA) 2031-11-17 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
AstraZeneca
Harvard Business School
McKinsey
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.